EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-GuérinSamantha Cambier, Jorg R. Oddens, Richard Sylvester et al.|European Urology|2015Cited by 639
Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical OutcomeBas W.G. van Rhijn, Ellen C. Zwarthoff, André N. Vis et al.|Journal of Clinical Oncology|2003Cited by 321
The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.Bas W.G. van Rhijn, Ellen C. Zwarthoff, Irene Lurkin et al.|PubMed|2001Cited by 309
<b> <i>FGFR3</i> </b> and <b> <i>P53</i> </b> Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell CarcinomaBas W.G. van Rhijn, Ellen C. Zwarthoff, Egbert R. Boevé et al.|Cancer Research|2004Cited by 223
Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder CancerBas W.G. van Rhijn, Theodorus van der Kwast, Tahlita C.M. Zuiverloon et al.|European Urology|2010Cited by 193